



HESI ANNUAL MEETING
JUNE 12-13, 2018
THE SCIENCE OF IMPLEMENTATION

FAIRMONT WASHINGTON DC HOTEL
2401 M STREET, NW, WASHINGTON, DC 20037, USA

TUESDAY JUNE 12, 2018

- 1:15– 6 pm HESI Annual Meeting Opening Plenary
- 1:15 – 1:25 pm Welcome and Chair's Remarks, and Meeting Overview – From HESI Chair, Dr. Ernie Harpur
- 1:25- 1:35 pm HESI and the Science of Implementation HESI Executive Director, Syril Pettit
- 1:35 –3:40 pm *Bringing Non-Animal Methods into Applied Practice* – Ongoing and Upcoming HESI efforts - Moderated by HESI Chair, Ernie Harpur.

This session will highlight work conducted by selected HESI Scientific Committees that demonstrates the organization's efforts to bring alternative, non-animal methods into practice to efficiently meet contemporary safety needs.

More, safer drugs to patients via novel and targeted in vitro assays for cardiac safety - Dr. Jean-Pierre Valentin, UCB (tentative)

Enhancing ecological health protection via computational approaches - Dr. Marlies Halder, European Commission Joint Research Center

Enhancing accuracy and efficiency in drug and chemical risk assessment - Pathway Based Genomic Markers – Dr. Carole Yauk, Health Canada

Break

Reducing risks to patients involved in clinical trials – A HESI CRA study – Dr. Curtis Maier - GlaxoSmithKline

3:40 – 4:20 pm A Different Perspective on Moving Science to Application – Intro by Charlene McQueen.

This speaker will provide perspectives from the venture funding arena around opportunities to address gaps in development and innovation.

Getting to the finish line: new approaches to funding gaps in the journey from lab to market - Practitioner perspectives on impact investments and other non-traditional funding tools to support innovation through the 'valley of death. John Parker, MBA, Founder & Managing Director, Springhood Impact Ventures.

4:20 – 6:00 pm [Science Forward: Microbial Science and Human and Environmental Health](#) -Emerging Issues Proposal
Microbial Testing and Health Risk Assessment - Introduction by Dr. Tim Gant, EIC Chair.

This session will highlight emerging science identified via HESI's annual Emerging Issues process. The session features input from experts who will identify key gaps in both ongoing research and the implementation of that research to protect human and environmental health. A proposal for a future HESI scientific initiative in this area will be presented.

[Wastewater treatment systems as reservoirs of antibiotic resistant bacteria: Should we be concerned?](#)
Dr. Kimberly Gilbride, Ryerson University.

6:00 pm [Meet the Speakers, Meet the Cmte Chairs, Meet the Staff – Brief Introduction to Facilitate Networking](#)

6:15 pm Welcome Reception for ALL with Dinner



WEDNESDAY JUNE 13, 2018

9:00 am – 10:30 am **Aligning Health Solutions with 'Real World Evidence' (Part I): Risk Frameworks for Protection of Public Health – Introduction by Dr. Tim Pastoor.**

This session will highlight the use of contemporary risk assessment frameworks, including HESI's RISK21, to integrate available toxicity and exposure information for use in real world health protection activities.

Puspo Edi Giriwono, PhD – Southeast Asia Food and Agricultural Science and Technology (SEAFAST) Center, Bogor Agricultural University (IPB), Bogor, Indonesia - **Probability scenario of 3-MCPD in fried chicken (a RISK21 Case Study) - 25 min plus 10 min Q&A**

Rose Omari, PhD - Science and Technology Policy Research Institute, Council for Scientific and Industrial Research, Accra, Ghana. **Risk assessment of aflatoxin in Weanimix (cereal-legume complementary food) - 25 min plus 10 min Q&A**

Panel Discussion 20 Minutes – Implementing Risk Assessment Tools that Span Geographic and Regulatory Borders: Opportunities and Challenges

10:30 am – 10:50 am BREAK

10:50 am – 12:30 pm **Aligning Health Solutions with 'Real World Evidence' (Part II): Gathering and Using Data from Diverse Sources – Introduction by Dr. Lois Lehman-McKeeman**

This session will provide highlight some of the novel technologies and methodologies with potential to significantly impact our perspectives on exposure and health. The topics here were identified in HESI's 2017 Scientific Foresight activity as critical areas of emerging science.

Natural Language Processing (NLP) Approaches to Generating Actionable Knowledge from Across Published Literature & Unpublished Reports - Taxiarchis Botsis, MS, PhD, Visiting Scientist, Office of Biostatistics & Epidemiology | Center for Biologics Evaluation and Research | FDA (*confirmed*) - 25 min plus 10 min Q&A

Implementing Health Information from Wearable Technology - Opportunities and Barriers - Dr Lukasz Piwek | Lecturer in Data Science, University of Bath School of Management (*confirmed*) – 25 min plus 10 min Q&A

Integrating Data into Health Decisions via Environmental Epidemiology – Intro to a New HESI Program- 20 min) – Dr. Heidi Erickson, Chevron (*confirmed*) - 25 min plus 10 min Q&A

12:30 pm – 2:00 pm **HESI Scientific Committee Leadership Recognition & Leadership Discussion (Lunch Provided) - All HESI Scientific Committee Chairs encouraged to attend. All meeting participants invited to participate in luncheon.**

2:00 pm [Oncologic Therapy Safety Assessment: Making Patient Quality of Life an Active Research Priority.](#)
Introduction – S Pettit

This session presents research on opportunities to implement meaningful changes in drug design, delivery, or support that will improve cancer patient outcomes. The research here evaluates opportunities to predict, prevent, or ameliorate adverse effects of lifesaving cancer therapies. The presenters are all recipients of 2017 HESI THRIVE grant awards.

HESI 2017 THRIVE Grantees Presentation (25 min, plus 10 min for questions)

- **Visualizing left ventricular microcirculatory perfusion effects in survivors of breast cancer and lymphoma**
 - Jennifer Jordan – PhD, Wake University School of Medicine
- **Supporting safer glucocorticoid-receptor targeted therapy for blood cancers**
 - Irina Budonova – MD, PhD, Northwestern University
- **Screening approaches for chemotherapy-induced peripheral neuropathy in breast cancer patients**
 - Barbara Ehrlich, PhD – Yale University
- **Genetic determinants of adverse events in cancer patients receiving immune checkpoint inhibition therapy**
 - Noha Abdel-Wahab, MD, PhD - UT MD Anderson Cancer Center

4:20pm [Awards and Recognitions](#)

4:45 pm [Adjourn](#)

6:00 pm – 8:00 pm *Speaker Dinner w Executive Committee (Invitation only)*